

Registered number: 06456614

AVEO PHARMA LIMITED


UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2017

FRIDAY



L7FES1R6
L21 28/09/2018 #5
COMPANIES HOUSE

AVEO PHARMA LIMITED
REGISTERED NUMBER: 06456614

BALANCE SHEET
AS AT 31 DECEMBER 2017

	Note	2017 £	2016 £
Current assets			
Debtors: amounts falling due within one year	3	646,113	646,113
		<u>646,113</u>	<u>646,113</u>
Total assets less current liabilities		646,113	646,113
Net assets		<u>646,113</u>	<u>646,113</u>
Capital and reserves			
Called up share capital		2	2
Other reserves	4	5,076,155	5,076,155
Profit and loss account	4	(4,430,044)	(4,430,044)
		<u>646,113</u>	<u>646,113</u>

For the year ended 31 December 2017 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:


 Michael Bailey
 Director

Date: 9/25/2018

The notes on pages 2 to 3 form part of these financial statements.

AVEO PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

1. General information

The principal activity of the company in the year under review was that of joint development of oncological therapeutic treatments for commercialisation within the European area. The Company is now dormant. Aveo Pharma Limited is a private company limited by shares registered in England and Wales. The registered office is 2 Temple Back East, Temple Quay, Bristol, Avon, BS1 6EG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

2.2 Foreign currency translation

Functional and presentation currency

The Company's functional currency is USD. This differs from the presentational currency which is GBP rounded to the nearest £. The reason for the difference is that the company files statutory accounts in the UK, however it belongs to the Aveo Pharmaceuticals Inc. group and the functional currency of the group is USD.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in the Statement of Comprehensive Income within 'other operating income'.

2.3 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

AVEO PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

3. Debtors

	2017 £	2016 £
Amounts owed by group undertakings	646,113	646,113
	<u>646,113</u>	<u>646,113</u>

4. Reserves

Other reserves

Other reserves represents the amount relating to additional paid in capital which exceeds the nominal value of the shares and represents capital contribution.

Profit and loss account

Profit and loss account represents the cumulative profits or losses net of dividends paid and other adjustments.

5. Related party transactions

The ultimate parent company is Aveo Pharmaceuticals Inc. (registered and incorporated in the United States of America). The largest and smallest group in which the results of the company are consolidated is that headed by Aveo Pharmaceuticals Inc. The consolidated accounts of this company are available to the public and may be obtained from www.aveooncology.com.

6. Ultimate Controlling party

The directors of the company do not consider there to be an ultimate controlling party.